Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
ABBVIE LIMITED,Upadacitinib,"Crohn's disease, severe, 2nd line biologic",Upadacitinib (RINVOQÂ®),Community and Hospital,Alimentary Tract and Metabolism
